Xenon Pharmaceuticals Inc. (XENE) — 10-Q Filings

10-Q Filings (6)

• Xenon's Losses Widen 43% Amid Soaring R&D Costs — Nov 3, 2025 Risk: high
  Xenon Pharmaceuticals Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $240,649 thousand, up from $168,64
• Xenon Continues R&D Spend, No Revenue in Q2 — Aug 11, 2025 Risk: high
  Xenon Pharmaceuticals Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net los
• Xenon Pharma Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  Xenon Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, includin
• Xenon Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Xenon Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and business operations, including
• Xenon Pharma Q2 2024 Update: Financials & Equity Offerings — Aug 8, 2024 Risk: medium
  Xenon Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial position and results of operations. Key financ
• Xenon Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Xenon Pharmaceuticals Inc. (XENE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Xenon Pharmaceuticals Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX